New issues generate millionaire boffins
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A computer software company with only 25 staff was valued on the stock market at pounds 30m yesterday after its shares rose to a 60 per cent premium on their first day of dealings.
Shares in Recognition Systems, which develops software used in database marketing, closed at 110p against the placing price of 70p. The placing raises pounds 3.3m of new money which will be used for expansion
The deal makes rich men of the two founders, David Bounds and Paul Gregory, who formed the company in 1989 and control 44 per cent of the stock. Though neither is selling shares, their combined stake is worth around pounds 14m on paper. Professor Bounds, a former professor of computer science and applied mathematics at Aston University, is a world authority on neural computing.
Paul Gregory is a former head of product development at Vickers, the defence group.
The sparkling debut continues the trend of academics turning their companies into stock market successes. The directors of City Technology, a gas sensors company that issued its pathfinder prospectus yesterday, formed the company at City University in London.
The directors of Vanguard Medica working on a migraine treatment are all eminent scientists. All made paper fortunes this month when the company's shares soared to a big premium on their first day of dealings.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments